SavedAdd your journal

Journals / Kırıkkale Üniversitesi Tıp Fakültesi Dergisi / 2026 / Cilt: 23 Sayı: 1

Effects of 72-Hour Trimethazidine in Open Heart Surgery on Myocardial Ischemia

AÇIK KALP CERRAHİSİNDE 72 SAATLİK TRİMETAZİDİN UYGULAMASININ MİYOKARD İSKEMİSİ ÜZERİNE ETKİLERİ

Hüseyin Gemalmaz(Özel Bahçelievler Memorial Hospital, Department of Cardiovascular Surgery, İstanbul Turkey)0000-0003-3995-3557
Yıldırım Gültekin(Kırıkkale Üniversitesi Tıp Fakültesi)0000-0002-9384-0556
Tuğrul Kural(ESKİŞEHİR OSMANGAZİ ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0003-3499-4915
Pages
49–58
Publication Date
2021-04-30
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Objective: The aim of this study is to show the effects of 72-hour long trimethazidine (TMZ) administration on myocardial ischemia before open heart surgery.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study is to show the effects of 72-hour long trimethazidine (TMZ) administration on myocardial ischemia before open heart surgery.
📊
Key Findings & Data:Objective: The aim of this study is to show the effects of 72-hour long trimethazidine (TMZ) administration on myocardial ischemia before open heart surgery.
💡
Conclusion & Impact:Objective: The aim of this study is to show the effects of 72-hour long trimethazidine (TMZ) administration on myocardial ischemia before open heart surgery.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Koroner bypass · trimetazidin · troponin I

Abstract

Objective: The aim of this study is to show the effects of 72-hour long trimethazidine (TMZ) administration on myocardial ischemia before open heart surgery.

Özet

Amaç: Bu çalışmanın amacı açık kalp cerrahisi öncesi 72 saatlik trimetazidin (TMZ) uygulamasının miyokard iskemisi üzerine etkilerini göstermektir.

🔖

Cite This Article

Gemalmaz, H., Gültekin, Y., Kural, T. (2021). Effects of 72-Hour Trimethazidine in Open Heart Surgery on Myocardial Ischemia. Kırıkkale Üniversitesi Tıp Fakültesi Dergisi, Cilt: 23 Sayı: 1, 49–58. https://doi.org/10.24938/kutfd.824624

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (40)

  1. Ascione R, Lloyd CT, Underwood MJ, Lotto AA, Pitsis AA, Angelini GD. Inflammatory response after coronary revascularization with or without cardiopulmonary bypass. Ann Thorac Surg. 2000;69(4):1198–204.
  2. Parissis T, Adamopoulos S, Farmakis D, Flippatos G, Paraskevaidis I, Kremastinos TH et al. Effect of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart. 2006;92(1):1768-72.
  3. Buckberg GD, Brazier JR, Nelson RL, Goldstein SM, McConnell DH, Cooper N. Studies of the effects of hypotermia on regional myocardial flow and metabolism during cardiopulmonary bypass. The adequately perfused beating, fibrilating and arrested heart. J Thorac Cardiovas Surg. 1977;73(1):87-94.
  4. Akgün S. Erişkin kalp cerrahisinde miyokard korunması. In: Duran E, ed. Kalp ve Damar Cerrahisi. 1st ed. İstanbul. Çapa Tıp Kitabevi, 2004:1091-106.
  5. Buckberg GD. The duality of cardiac surgery: mechanical and metabolic objctive. In: Salerno TA, Ricci M, eds. Myocardial Protection. 1st ed. New Jersey. Blackwell Publishing, 2004:13-7.
  6. Carden DL, Granger DN. Pathophysiology of ischemia reperfusion injury. J Pathol. 2000;190(6):255-66.
  7. Dhalla NS, Elmoselhi AB, Hata T, Makino N. Status of myocardial antioxidants in ischemia-reperfusion injury. Cardivasc Res. 2000;47(3):446-56.
  8. Reiter RJ, Tan DX. Melatonin: A novel protective agent against oxidative injury of the ischemic-reperfused heart. Cardiovascular Research. 2003;58(1):10-9.
  9. Gross GJ, Kersten JR, Warltier DC. Mechanisms of postischemic contractile dysfunction. Ann Thorac Surg. 1999;68(5):1898-904.
  10. Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia- reperfusion injury. Cardiovasc Res. 1999;43(4):860-78.
  11. Reiter RJ. The aging pineal and its physiological consequences. BioEssays. 1992;14(3):169-75.
  12. Efthimiadis A, Cheiridou M, Lefkos N, Doumalas A, Arampatzis P, Tsapas G. The predictive value of TnT in patients who underwent an extracardiac surgery operation. Acta Cardiol. 1995;50(4):309-13.
  13. Hamm CW, Katus HA. New biochemical markers for myocardial cell injury. Curr Opin Cardiol. 1995;10(4):355-60.
  14. Bertinchont JP, Larue C, Pernel I, Ledermann B, Fabbro-Peray P, Beck L et al. Release kinetics of serum cardiac troponin I in ischemic myocardial injury. Clin Biochem. 1996;29(6):587-94.
  15. Collinson PO. Troponin T or troponin I or CK-MB (or none?). Eur Heart J. 1998;19(4):16-24.
  16. Carrier M, Pellerin M, Perrault LP, Solymoss BC, Pelletier LC. Troponin levels in patients with myocardial infarction after coronory artery bypass graftting. Ann Thorac Surg. 2000;96(2):435-40.
  17. Adams JE, Sicard GA, Allen BT, Bridwell KH, Lenke LG, Dávila-Román VG et al. Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I N Engl J Med. 1994;330(10):670-4.
  18. Timour Q, Harpey C, Durr F, Faucon G. Is the antianginal action of trimetazidine independent of hemodynamic changes? Cardiovase Dugs Ther. 1991;5(6):1043-44.
  19. Chierchia SL, Fragasso G. Protective effects of trimetazidine on ischaemic myocardial dysfunction. European Heart Journal. 1999;1(0):24-27.
  20. Chocron S, Alwan K, Toubin G, Clement F, Kaili D, Taberlet C et al. Crystalloid cardioplegia route of delivery and cardiac troponin T release. Ann Thorac Surg. 1996;62(2):481-5.
  21. Harpey C, Clauser P, Labrid C, Freyria JL, Jean‐Pierre PJP. Trimetazidin, a cellular anti ischemic agent. Cadiovasc. Drugs Rev. 1989;6(4):292-312.
  22. Lopaschuk GD, Barr R, Thomas PD, Dyck JRB. Beneficial effects of trimetazidine in ex vivo working ıschemic hearts are due to a stimulation of glucose oxidation secondary to ınhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circulation Research. 2003;93(3):33–7.
  23. Carr JA, Haithcokk BE, Paone G. Long term out come after coronary artery bypass garfting in patients with severe left ventrikular dysfonction: Ann Thorac Surg. 2002;74(5):1531-36.
  24. Barber DA, Harris SR. Oxygen free radicals and antioxidants: a review The use of antioxidant vitamin supplements to scavenge free radicals could decrease the risk of disease. Am Pharm. 1994;34(9):26-35.
  25. Allman K.C. Shaw LJ, Hachamovitch D. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary arter disease and left ventrikular dysfonction: A meta analysis. JACC. 2002;39(7):1151-58.
  26. Kılınç K, Kılınç A. Oksijen toksisitesinin aracı molekülleri olarak oksijen radikalleri. Hacettepe Tıp Dergisi. 2002;33(2):110-8.
  27. Yekeler İ, Abanoz M, Akçay F, Varoğlu E, Ege E, Ateş A ve ark. Kalp kapak replasmanı ve koroner bypass cerrahisi uygulanan hastalarda ekstrakorporeal dolaşımın endotelin-1 ve atriyal natriüretik peptid düzeyleri üzerine etkisi. Türk Göğüs Kalp Damar Cer Derg. 1997;5(3):104-11.
  28. Mehta JL, Nichols WW, Saldeen TG, Chandna VK, Nicolini FA, Lawson DL et al. Superoxide dismutase decreases reperfusion arrhythmias and preserves myocardial function during thrombolysis with tissue plasminogen activator. J Cardiovasc Pharmacol. 1990;16(1):112-20.
  29. Fabiani JN, Ponzio O, Emerit I, Massonet-Caste S, Paris M, Chevalier P et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg. 1992;33(4):486-91.
  30. Aussedat J, Ray A, Kay L, Verdys M, Harpey C, Rossi A. Improvement of long-term preservation of isolated arrested rat heart: beneficial effect of the antiischemic agent trimetazidine. J Cardiovasc Pharmacol. 1993;21(1):128-35.
  31. El Banani H, Bernard M, Baetz D, Cabanes E, Cozzone P, Lucien A et al. Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischaemia. Cardiovasc Res. 2000;47(4):688-96.
  32. Vedrinne JM, Vedrinne C, Bompard D, Lehot JJ, Boisell JP, Champsaui G. Myocardial production during coronary bypass graft surgery:a randomized, double blind, placebo controlled study with Trimetazidine. Anest Analg. 1996;82(4):712-8.
  33. Koçarslan A, Hazar A, Aydın MS, Aksoy N, Göz M The impact of preoperative trimetazidine use on oxidative parameters in patients undergoing coronary bypass surgery. Dicle Tıp Dergisi. 2013;40(4):589-96.
  34. Zhang N, Lei J, Liu Q, Huang W, Xiao H, Lei H. The effectiveness of preoperative trimetazidine on myocardial preservation in coronary artery bypass graft patients: a systematic review and meta-analysis. Cardiology. 2015;131(2):86-96.
  35. Tünerir B, Colak O, Alata¬ O, Besogul Y, Kural T, Aslan R. Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting. Ann Thorac Surg. 1999;68(6):2173-6.
  36. Xu P, Wen B, Jiao Z, Liu C, Zhao W: The cardioprotective effects of trimetazidine during off-pump coronary artery bypass grafting. Henan Med Res. 2014;23(3):29-31.
  37. Sher-i-Murtaza M, Zubair M, Jalal A. Is there any benefit of preoperative oral trimetazidine in coronary artery bypass graft? J Pak Med Assoc. 2012;62(12):1271-6.
  38. Parsomet V, Dean D, Bernstein AD. A method of uniform stratification of risk for evaluating the results of surgery in acquired adult heart diasease. Circulation. 1989;79(6 [Suppl. 2]):13-22.
  39. Lee TH, Thomas EJ, Ludwing LE, Sacks DB, Johnson PA, Donaldson MC et al. TnT as a marker for myocardial ischemia in patients undergoing major cardiac surgery. Am. J. Cardiol. 1996;77(12):1031-6.
  40. Aksun M, Aksun S, Kestelli M, Kuru V, Tanyeli HF, Girgin S et al. The postoperatıve effects of use of trimetazidine before the coronary artery bypass graft surgery. Niger J Clin Pract. 2019;22(7):997-1001.